Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALPL | P05186 | 1/20 | 0.34 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.32 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.32 |
| ▸ | TUBB | P07437 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25518667 | 0.94 | POLB (0.40) | POLBALPLCYP17A1NAMPTALDH1A1 | |
| SCHEMBL30427353 | 0.90 | CHRNB4 (0.37) | POLBCYP17A1NAMPTALDH1A1KDM4E | |
| SCHEMBL30427371 | 0.90 | POLB (0.34) | POLBALPLCYP17A1NAMPTALDH1A1 | |
| SCHEMBL30427346 | 0.86 | MEN1 (0.36) | ALPLMAPTHTTKMT2APTGS1 | |
| SCHEMBL25188299 | 0.82 | POLB (0.44) | POLBALPLCYP17A1KDM4ECHRNB4 | |
| SCHEMBL31019969 | 0.82 | POLB (0.44) | POLBALPLCYP17A1KDM4ECHRNB4 | |
| Abeprazan SCHEMBL18196939 | 0.82 | HTR6 (0.39) | MAPTKMT2A | |
| Abeprazan SCHEMBL29443418 | 0.82 | HTR6 (0.39) | MAPTKMT2A | |
| Abeprazan SCHEMBL29719476 | 0.82 | HTR6 (0.39) | MAPTKMT2A | |
| SCHEMBL25314470 | 0.81 | SLC6A4 (0.37) | POLBKMT2APTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250051275-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | HANA PHARM CO., LTD. (KR) | 2025-02-13 | — | — | US | claimed |
| EP-4434966-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | Hana Pharm. Co. Ltd. (KR) | 2024-09-25 | — | — | EP | claimed |
| CN-118451060-A | Pyrrole derivative or pharmaceutically acceptable salt thereof and composition for preventing, improving or treating gastrointestinal diseases comprising the same as active ingredient | 合娜制药株式会社 | 2024-08-06 | — | — | CN | claimed |
| WO-2023090942-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | 하나제약 주식회사 | 2023-05-25 | — | — | WO | claimed |
| US-20250051275-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | HANA PHARM CO., LTD. (KR) | 2025-02-13 | — | — | US | disclosed |
| EP-4434966-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | Hana Pharm. Co. Ltd. (KR) | 2024-09-25 | — | — | EP | disclosed |
| CN-118451060-A | Pyrrole derivative or pharmaceutically acceptable salt thereof and composition for preventing, improving or treating gastrointestinal diseases comprising the same as active ingredient | 合娜制药株式会社 | 2024-08-06 | — | — | CN | disclosed |
| WO-2023090942-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALT THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | 하나제약 주식회사 | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250051275-A1 | PYRROLE DERIVATIVE OR PHARMACEUTICALLY OR SITOLOGICALLY ACCEPTABLE SALTS THEREOF, AND COMPOSITION FOR PREVENTION, AMELIORATION OR TREATMENT OF GASTROINTESTINAL DISORDERS COMPRISING SAME AS ACTIVE INGREDIENT | STOM, SI, PGC | POLB 3324/4885ALPL 2068/4885CYP17A1 3594/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.